Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Blue Water Biotech, Bone Biologics, Carl Zeiss Meditec, Elutia, Harvard Apparatus Regenerative Technology, Onconetix, Ophthalmic Research Center, Proteomedix, Retrieve Medical, Serf, Stryker, Thubrikar.
Neuroone Medical Technologies Corp. received U.S. FDA 510(k) clearance for its Onerf ablation system which is capable of both recording electrical activity and ablation of nervous tissue.
Zimvie Inc. will sell its spine business to private equity investor H.I.G. Capital for $375 million, a move that should clean up its balance sheet and allow it to focus on the more profitable dental business. The deal is structured as $315 million in cash plus a promissory note for $60 million with an interest rate of 10%, compounded semi-annually.
After years of battling to retain its hold on Grail Inc., Illumina Inc. finally announced that it will be unwinding the ill-fated acquisition of the multi-cancer early detection test maker. In addition to stiff opposition from activist investor Carl Icahn that cost Illumina’s previous CEO and board chair their positions, European and U.S. regulators have consistently opposed the deal.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Fuse Oncology, Inspire2live, Median Technologies, Oncoinv, Pasrel-Imagerie, Scitara, Seekin, Snowflake, Vapotherm.
Total med-tech deal value through November is up 34.42% over the same period last year and is also higher than every comparable period from 2019-2022. Conversely, med-tech M&A value experienced a decline of 64.07% compared to the first 11 months of 2022.
RSS
